Abstract: Field of application: the invention relates to biotechnology, can be used in the food industry, medicine and cosmetology in the prevention and/or treatment of diseases associated with immunodeficiencies and respiratory viral infections. The proposed food, cosmetic and pharmaceutical composition with an immunomodulating and protective antiviral effect additionally has the ability to completely prevent infection by a number of viruses, including influenza, rotavirus and coronavirus, as well as stimulate the immune system more than individual probiotics.

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

Abstract: Collagen compositions, methods for preparing those collagen compositions, and 3D constructs formed from those collagen compositions are provided. In particular, methods of isolating collagen that exhibits an enhanced rate of gelling, such collagen compositions, and 3D constructs formed from such collagen compositions are provided.

Abstract: Filaments that contain a filament-forming material and an additive, nonwoven webs, and methods for making such filaments are provided.

Abstract: The present invention relates to an internal hole filler of an abutment for implant, which includes first polytetrafluoroethylene (first PTFE) and second polytetrafluoroethylene (second PTFE), wherein tensile strength measured after sintering the first PTFE is in a range of 20 MPa or more to less than 28 MPa, and tensile strength measured after sintering the second PTFE is 28 MPa or more, and a method of filling an internal hole of the abutment for implant.

Abstract: The invention relates primarily to a method of modulation, preferably of in vitro and/or in vivo modulation, of the cold menthol receptor TRPM8, wherein the receptor is contacted with at least one modulator selected from the group consisting of the compounds of the structure type 1 described herein. The present invention further relates to corresponding uses and compositions comprising such compounds.

Abstract: A method for treatment, prevention, or reduction of one-time or recurring viral outbreaks, for suppression of development or growth of chronic viral infections, or for prevention or treatment of viral infections, the method including, administering a synthetic lysine analog or mimetic, where the synthetic lysine analog or mimetic antagonizes or competes with an amino acid or other biological agent required by a virus to replicate or spread. Additionally, a composition to treat, prevent, or reduce one-time or recurrent viral outbreaks, suppress development or growth of chronic viral infections, or to prevent or treat viral infections, the composition including, a synthetic lysine analog or mimetic, where the synthetic lysine analog or mimetic antagonizes or competes with an amino acid or other biological agent required by a virus to replicate or spread.

Abstract: The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum includes water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the chewing gum includes one or more high intensity sweeteners in an amount of 0.01 to 1% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

Abstract: Aqueous cosmetic compositions comprising at least 20% by weight of an aqueous component and a lipophilic component characterized in that the lipophilic component comprises at least one ester selected from neopentylglycol dipelargonate, glycerol tripelargonate, pentaerythritol tetrapelargonate or mixtures thereof.

Abstract: Methods of increasing sIgA and mucin 5B levels in an individual's oral cavity are disclosed. The methods comprise applying to the individual's oral cavity in an amount effective to increase sIgA and mucin 5B levels in the individual's oral cavity, an oral care composition comprising: zinc phosphate, stannous fluoride and optionally, an organic acid buffer system.

Abstract: Provided are HPMCAS powder having high solubility when dissolved in a solvent and being capable of suppressing generation of undissolved materials; and a method for producing the powder. More specifically, provided is hypromellose acetate succinate powder having an average ratio of L to D of from 2.0 to 3.0, wherein L and D mean maximum and minimum diameters of each particle, respectively. Also provided is a method for producing a hypromellose acetate succinate, comprising the steps of: dissolving hypromellose powder in a solvent, esterifying the dissolved hypromellose with succinic anhydride and acetic anhydride in the presence of a catalyst to obtain a reaction mixture, and mixing the reaction mixture with water to precipitate hypromellose acetate succinate, wherein the reaction mixture just before being mixed with the water has a viscosity of from 100 to 200 Pa·s.

Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.

Abstract: A pharmaceutical composition containing synthetic Cannabidiol and its use in obtaining a medication for the treatment of neurological disorders, as well as the main excipients used in the production process, in addition to its small, medium, and large-scale preparation process. The use of the composition for the treatment of neurological disorders in human or animal populations, in particular in the treatment of Parkinson's disease, in the range of 300 to 850 mg/day or at daily doses of 100 to 1750 mg for neuroprotective action.

Abstract: Described herein are complexes comprising a cationic antibacterial agent and a metal salt; oral care compositions comprising same; along with methods of making and using these complexes and compositions.

Abstract: The present disclosure relates to chewing gum or lozenge with cannabinoids and menthol including a liquid-filled chewing gum or lozenge with a chewing gum base shell or lozenge candy shell enclosing an internal void therein and a liquid filling in the void, the liquid-filled chewing gum or lozenge including cannabinoids and menthol. The menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.

Abstract: The invention relates to oil-in-water emulsion in which specific oils (e.g., lauric oils) are used in the oil phase while surprisingly maintaining excellent transparency. In one aspect, said emulsions comprise fatty acid in oil phase. The invention comprises an energy efficient process for making said fatty acid containing transparent nanoemulsions.

Abstract: A method of treating respiratory system tissue, includes operations of generating a plume of particles of a treating solution from a nebulizer, inhaling particles of the treating solution, delaying exhalation of an inhalation having particles of the treating solution therein, and determining whether a dose of the treating solution has been delivered, wherein the treating solution is a solution of at least 40% ethyl alcohol, by volume.

Abstract: The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Abstract: The invention relates to a preparation containing: (i) a composition containing (a) one, two or a plurality of compounds selected from the group consisting of (a1) alcohol monoterpenes of formula (I) in which R1 is H or methyl, R2 is H or C2-alkenyl, und R3 is a linear or branched, saturated or unsaturated hydrocarbon radical with 4 to 10 carbon atoms, and the enantiomers, diastereomers, racemates, solvates and physiologically compatible salts thereof, and/or (a2) bicyclic epoxy-monoterpenes, (b) at least two lactones of formula (II) in which R4 is H or methyl, R5 is a linear or branched, saturated or unsaturated hydrocarbon radical with 2 to 10 hydrocarbon atoms and n is the number 1 or 2, and the enantiomers, diastereomers and racemates thereof, (c) one, two or a plurality of solvents selected from the group consisting of ethanol, water, dipropylene glycol (DPG), diethyl phtalate (DEP), propylene glycol (PG), isopropyl myristate (IPM), isopropyl palmitate (IPP), triethyl citrate (TEC), triacetin (TRI), 1,2-

Abstract: Choline alfoscerate is useful for treating cognitive dysfunction associated with cerebrovascular diseases and degenerative brain diseases. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with neuropathic pain, it can significantly reduce the pain intensity and the occurrence of neuropathic pain. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing neuropathic pain and a health functional food composition for improving neuropathic pain and may also be used for a method for treating neuropathic pain by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating neuropathic pain.